Other News

Ablacon Announces Martin Grasse as CEO and Clinical Study Progress

MENLO PARK, Calif., June 22, 2021 /PRNewswire/ — Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue with the company as Executive Chairman. “Marty has demonstrated exceptional leadership capabilities […]

Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have been in the news in recent days

– Genetics allows the study of risk related to hereditary cardiovascular disease, with special relevance in cardiomyopathies, arrhythmias and vascular involvement syndromes that may involve risk of sudden death. – The myCardio service designed by Veritas Intercontinental, a company focused on the study of genetic predisposition, includes all genes recommended […]

Remote Cardiac Monitoring Leader Implicity Appoints Tim Laird as New VP of Sales North America to Enhance Leadership Team

Proven sales leader brings more than 20 years of healthcare experience to help Implicity accelerate its expansion into the US market CAMBRIDGE, Mass., June 22, 2021 /PRNewswire/ — Implicity, a leader in remote patient monitoring software and cardiac data management solutions, today announced the addition of Tim Laird as Vice President of Sales–North America. Laird […]

JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing

Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne’s Phase 2b Trial Preparedness and Execution LAS VEGAS, June 22, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection […]

BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021

Cell Therapy Platform Demonstrates High Dose CD34+ Cell Performance Characteristics in Patients with Ischemic Heart Failure SAN CARLOS, Calif., June 22, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its CardiAMP […]

Philips announces first patient enrollment in DEFINE GPS global multicenter study to assess superiority of PCI procedures guided by co-registered iFR and interventional angiography

June 22, 2021 First patient enrolled in global randomized controlled trial with up to 3,200 participants at 100 sites comparing patient outcomes after percutaneous coronary intervention (PCI) procedures guided by iFR data co-registered on the angiogram (interventional X-ray image) versus the current standard of care, an angiogram alone One of the largest-ever […]

Verve Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) — Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced initial public offering of 16,141,157 shares of its common stock, which includes 2,105,368 shares […]

Cardiac Insight Announces 4th Generation of Its Cardea SOLO™ ECG Monitoring System

Leading ECG analysis platform speeds time to diagnosis and creates greater clinical efficiencies with expanded software capabilities BELLEVUE, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc. (“Cardiac Insight” or the “Company”) is a healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and […]

Imbria Pharmaceuticals Announces Enrolment of the First 10 Patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes

BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the first 10 (ten) patients were dosed in the IMPROVE-DiCE Phase 2a, open-label study of IMB-1018972 […]